Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 2
1969 3
1970 2
1971 4
1972 3
1973 2
1974 1
1975 8
1976 4
1977 8
1978 12
1979 13
1980 7
1981 4
1982 5
1983 3
1984 4
1985 7
1986 6
1987 13
1988 9
1989 11
1990 9
1991 11
1992 10
1993 9
1994 15
1995 16
1996 11
1997 14
1998 12
1999 16
2000 12
2001 9
2002 12
2003 10
2004 10
2005 9
2006 16
2007 5
2008 8
2009 5
2010 5
2011 6
2012 8
2013 5
2014 5
2015 4
2016 5
2017 3
2018 4
2019 2
2020 1
2021 3
2022 4
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

398 results

Results by year

Filters applied: . Clear all
Page 1
Safety and Efficacy of AGN-190584 in Individuals With Presbyopia: The GEMINI 1 Phase 3 Randomized Clinical Trial.
Waring GO 4th, Price FW Jr, Wirta D, McCabe C, Moshirfar M, Guo Q, Gore A, Liu H, Safyan E, Robinson MR. Waring GO 4th, et al. JAMA Ophthalmol. 2022 Apr 1;140(4):363-371. doi: 10.1001/jamaophthalmol.2022.0059. JAMA Ophthalmol. 2022. PMID: 35238902 Free PMC article. Clinical Trial.
IMPORTANCE: AGN-190584 (Allergan, an AbbVie company) is an optimized topical formulation of pilocarpine hydrochloride, 1.25%, designed for managing presbyopia and enhanced with a proprietary vehicle. OBJECTIVE: To evaluate the efficacy and safety of pilocarpine hydr …
IMPORTANCE: AGN-190584 (Allergan, an AbbVie company) is an optimized topical formulation of pilocarpine hydrochloride, 1.25%, designe …
Comparison of the 1 and 2% pilocarpine mouthwash in a xerostomic population: a randomized clinical trial.
Motamed B, Alaee A, Azizi A, Jahandar H, Fard MJK, Jafari A. Motamed B, et al. BMC Oral Health. 2022 Dec 1;22(1):548. doi: 10.1186/s12903-022-02576-6. BMC Oral Health. 2022. PMID: 36457091 Free PMC article. Clinical Trial.
AIMS & BACKGROUND: Pilocarpine is an accepted treatment for xerostomia, but limited research has been conducted on the oral, topical form. ...Moreover, the salivary flow in the 2% pilocarpine mouthwash group was significantly higher than the 1% pilocarpine …
AIMS & BACKGROUND: Pilocarpine is an accepted treatment for xerostomia, but limited research has been conducted on the oral, topi …
Safety and Efficacy of Twice-Daily Pilocarpine HCl in Presbyopia: The Virgo Phase 3, Randomized, Double-Masked, Controlled Study.
Kannarr S, El-Harazi SM, Moshirfar M, Lievens C, Kim JL, Peace JH, Safyan E, Liu H, Zheng S, Robinson MR. Kannarr S, et al. Am J Ophthalmol. 2023 Sep;253:189-200. doi: 10.1016/j.ajo.2023.05.008. Epub 2023 May 5. Am J Ophthalmol. 2023. PMID: 37149245 Free article. Clinical Trial.
Key safety measures included treatment-emergent adverse events (TEAEs) and some ocular measurements. Pilocarpine plasma levels were assessed in approximately 10% of enrolled participants. ...The most common TEAE was headache, reported in 10 participants (8.8%, Pilo group) …
Key safety measures included treatment-emergent adverse events (TEAEs) and some ocular measurements. Pilocarpine plasma levels were a …
Efficacy and Safety of Tolterodine and Pilocarpine in Patients with Overactive Bladder.
Ko KJ, Kim KH, Kim SW, Kim SO, Seo JT, Choo MS, Lee JZ, Oh SJ, Kim HG, Min KS, Kim JH, Lee KS. Ko KJ, et al. J Urol. 2019 Sep;202(3):564-573. doi: 10.1097/JU.0000000000000281. Epub 2019 Aug 8. J Urol. 2019. PMID: 31009289 Clinical Trial.
PURPOSE: We evaluated the efficacy and safety of a combination of 2 mg tolterodine and 9 mg pilocarpine, vs tolterodine monotherapy in patients with overactive bladder. ...Changes from baseline in the total xerostomia inventory score and the visual analogue scale for dry m …
PURPOSE: We evaluated the efficacy and safety of a combination of 2 mg tolterodine and 9 mg pilocarpine, vs tolterodine monotherapy i …
Safety and efficacy of oral pilocarpine in radiation-induced xerostomia in oropharyngeal carcinoma patients.
Kaur H, Singh Banipal RP, Singh H, Sonik YA, Sandhu SK. Kaur H, et al. J Cancer Res Ther. 2023 Apr-Jun;19(3):788-792. doi: 10.4103/jcrt.jcrt_2346_21. J Cancer Res Ther. 2023. PMID: 37470612 Free article. Clinical Trial.
AIMS: We aimed to evaluate the efficacy and safety profile of oral pilocarpine in radiation-induced xerostomia. MATERIALS AND METHODS: Sixty patients with oropharyngeal carcinoma were planned for radiotherapy and divided into two arms randomly: Arm A (30 patients) received …
AIMS: We aimed to evaluate the efficacy and safety profile of oral pilocarpine in radiation-induced xerostomia. MATERIALS AND METHODS …
Pupillometry in Chagas disease.
Vargas D, Castro C. Vargas D, et al. Arq Bras Oftalmol. 2018 Jun;81(3):195-201. doi: 10.5935/0004-2749.20180041. Arq Bras Oftalmol. 2018. PMID: 29924199 Free article. Clinical Trial.
The relative pupillary constriction amplitude did not differ between the two groups (p=0.39, mean difference -1.15%). There was hypersensitivity to dilute pilocarpine in 8 (10%) of the chagasic patients in the right eye and in 2 (2.5%) in the left eye and in 1 (1.25%) in b …
The relative pupillary constriction amplitude did not differ between the two groups (p=0.39, mean difference -1.15%). There was hypersensiti …
Clinical safety, tolerability and efficacy of combination tolterodine/pilocarpine in patients with overactive bladder.
Dmochowski RR, Staskin DR, Duchin K, Paborji M, Tremblay TM. Dmochowski RR, et al. Int J Clin Pract. 2014 Aug;68(8):986-94. doi: 10.1111/ijcp.12409. Epub 2014 Mar 25. Int J Clin Pract. 2014. PMID: 24666884 Clinical Trial.
Tolterodine/pilocarpine (2/9) was associated with consistently lower Visual Analogue Scale (VAS) scores for all dry mouth parameters compared with tolterodine alone. ...The combination was well tolerated, and the adverse effects observed were consistent with the known safe …
Tolterodine/pilocarpine (2/9) was associated with consistently lower Visual Analogue Scale (VAS) scores for all dry mouth parameters …
Effect of oral pilocarpine on post-irradiation xerostomia in head and neck cancer patients: a single-center, single-blind clinical trial.
Chitapanarux I, Kamnerdsupaphon P, Tharavichitkul E, Sumitsawan Y, Sittitrai P, Pattarasakulchai T, Lorvidhaya V, Sukthomya V, Pukanhaphan N, Traisatit P. Chitapanarux I, et al. J Med Assoc Thai. 2008 Sep;91(9):1410-5. J Med Assoc Thai. 2008. PMID: 18843872 Clinical Trial.
OBJECTIVE: The authors determined the efficacy and safety of oral pilocarpine tablet in symptomatic relief of post-radiation xerostomia in head and neck cancer patients. ...Adverse effects of placebo included mild headache, nausea, and vomiting. CONCLUSION: Oral pilocar …
OBJECTIVE: The authors determined the efficacy and safety of oral pilocarpine tablet in symptomatic relief of post-radiation xerostom …
Decreased salivary flow rate as a dipsogenic factor in hemodialysis patients: evidence from an observational study and a pilocarpine clinical trial.
Sung JM, Kuo SC, Guo HR, Chuang SF, Lee SY, Huang JJ. Sung JM, et al. J Am Soc Nephrol. 2005 Nov;16(11):3418-29. doi: 10.1681/ASN.2005040346. Epub 2005 Sep 21. J Am Soc Nephrol. 2005. PMID: 16177001 Clinical Trial.
In the interventional trial, the test drug was 5 mg of oral pilocarpine solution or placebo. Sixty hyperdipsic HD patients (IDWG% > 2%/d) were randomly assigned to either the sequence pilocarpine (2 wk)-washout (3 wk)-placebo (2 wk)-washout (2 mo)-placebo (3 mo) …
In the interventional trial, the test drug was 5 mg of oral pilocarpine solution or placebo. Sixty hyperdipsic HD patients (IDWG% &gt …
Pilocarpine and artificial saliva for the treatment of xerostomia and xerophthalmia in Sjogren syndrome: a double-blind randomized controlled trial.
Cifuentes M, Del Barrio-Díaz P, Vera-Kellet C. Cifuentes M, et al. Br J Dermatol. 2018 Nov;179(5):1056-1061. doi: 10.1111/bjd.16442. Epub 2018 May 29. Br J Dermatol. 2018. PMID: 29432648 Clinical Trial.
BACKGROUND: Sjogren syndrome (SS) is associated with xerostomia and xerophthalmia. Pilocarpine has been shown to stimulate the secretion of saliva. OBJECTIVES: To investigate and compare the efficacy of pilocarpine and artificial saliva as symptomatic treatments for …
BACKGROUND: Sjogren syndrome (SS) is associated with xerostomia and xerophthalmia. Pilocarpine has been shown to stimulate the secret …
398 results